Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. [electronic resource]
Producer: 20120614Description: 485-95 p. digitalISSN:- 1556-1380
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Apoptosis -- drug effects
- Blotting, Western
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cell Proliferation -- drug effects
- Drug Synergism
- Enzyme-Linked Immunosorbent Assay
- ErbB Receptors -- antagonists & inhibitors
- Estradiol -- analogs & derivatives
- Estrogen Receptor Modulators -- pharmacology
- Estrogens -- pharmacology
- Female
- Fluorescent Antibody Technique
- Fulvestrant
- Humans
- Immunoenzyme Techniques
- Lung Neoplasms -- drug therapy
- Mice
- Mice, SCID
- Piperidines -- pharmacology
- Protein Kinase Inhibitors -- pharmacology
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Quinazolines -- pharmacology
- RNA, Messenger -- genetics
- Real-Time Polymerase Chain Reaction
- Tumor Cells, Cultured
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Vascular Endothelial Growth Factor Receptor-3 -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.